{Reference Type}: Journal Article
{Title}: Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings.
{Author}: Laich Y;Georgiou M;Fujinami K;Daich Varela M;Fujinami-Yokokawa Y;Hashem SA;Cabral de Guimaraes TA;Mahroo OA;Webster AR;Michaelides M;
{Journal}: Ophthalmology
{Volume}: 131
{Issue}: 7
{Year}: 2024 Jul 24
{Factor}: 14.277
{DOI}: 10.1016/j.ophtha.2024.01.027
{Abstract}: <B>OBJECTIVE: </B>To analyze the genetic findings, clinical spectrum, and natural history of Best vitelliform macular dystrophy (BVMD) in a cohort of 222 children and adults.<BR><B>METHODS: </B>Single-center retrospective, consecutive, observational study.<BR><B>METHODS: </B>Patients with a clinical diagnosis of BVMD from pedigrees with a likely disease-causing monoallelic sequence variant in the BEST1 gene.<BR><B>METHODS: </B>Data were extracted from electronic and physical case notes. Electrophysiologic assessment and molecular genetic testing were analyzed.<BR><B>METHODS: </B>Molecular genetic test findings and clinical findings including best-corrected visual acuity (BCVA), choroidal neovascularization (CNV) rates, and electrophysiologic parameters.<BR><B>RESULTS: </B>Two hundred twenty-two patients from 141 families were identified harboring 69 BEST1 variants. Mean age at presentation was 26.8 years (range, 1.3-84.8 years) and most patients (61.5%) demonstrated deterioration of central vision. Major funduscopic findings included 128 eyes (30.6%) with yellow vitelliform lesions, 78 eyes (18.7%) with atrophic changes, 49 eyes (11.7%) with fibrotic changes, 48 eyes (11.5%) with mild pigmentary changes, and 43 eyes (10.3%) showing a vitelliruptive appearance. Mean BCVA was 0.37 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/47) for the right eye and 0.33 logMAR (Snellen equivalent, 20/43) for the left eye at presentation, with a mean annual loss rate of 0.013 logMAR and 0.009 logMAR, respectively, over a mean follow-up of 9.7 years. Thirty-seven patients (17.3%) received a diagnosis of CNV over a mean follow-up of 8.0 years. Eyes with CNV that received treatment with an anti-vascular endothelial growth factor (VEGF) agent showed better mean BCVA compared with eyes that were not treated with an anti-VEGF agent (0.28 logMAR [Snellen equivalent, 20/38] vs. 0.62 logMAR [Snellen equivalent, 20/83]). Most eyes exhibited a hyperopic refractive error (78.7%), and 13 patients (6.1%) received a diagnosis of amblyopia. Among the 3 most common variants, p.(Ala243Val) was associated with a later age of onset, better age-adjusted BCVA, and less advanced Gass stages compared with p.(Arg218Cys) and p.(Arg218His).<BR><B>CONCLUSIONS: </B>BVMD shows a wide spectrum of phenotypic variability. The disease is very slowly progressive, and the observed phenotype-genotype correlations allow for more accurate prognostication and counselling.<BR><B>BACKGROUND: </B>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.